RxDoctor Payments DataLook up a doctor →

Irl Hirsch

Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1881770642

Payments from drug & device makers

$2,393,788in general payments, 2019–2025

Across 398 payments — averaging $6014.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$872K
  • Insulet Corporation$567K
  • Tandem Diabetes Care, Inc.$439K
  • Mannkind Corporation$174K
  • Sequel Med Tech, LLC$106K
  • Abbott$85K
  • plus $151K from 13 others
$237in research payments, 2019–2025

Across 3 payments — averaging $79.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Dexcom, Inc.$237

What the payments were for

  • Consulting fees$99,64352%
  • Speaking & faculty fees$31,42516%
  • Travel & lodging$53,79228%
  • Food & beverage$7,1094%
  • Gifts$590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,393,788 in reported general payments places this provider in the 95th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.

See all endocrinology, diabetes & metabolism providers in Washington

Medicare billing

Part B allowed, 2024
$17,414
Medicare patients
81
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$94,328
JardianceEmpagliflozin26$40,727
MounjaroTirzepatide13$15,041
Humalog Kwikpen U-100Insulin Lispro22$14,681
LyumjevInsulin Lispro-Aabc15$10,674
HumalogInsulin Lispro45$10,006
Tresiba Flextouch U-100Insulin Degludec17$8,136
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$7,200
Novolog FlexpenInsulin Aspart23$6,217
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,246
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$2,252
Atorvastatin Calcium93$1,001
Levothyroxine Sodium52$858
Ezetimibe31$705
Rosuvastatin Calcium38$667

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →